Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)
Clinical trial NCT05298423 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05298423
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-03
- Primary completion
- 2026-06-15
- Enrollment
- 611
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.